FDA-Approved Oligonucleotide Therapies in 2017.
Stein CA, Castanotto D.
Mol Ther. 2017 Mar 30. pii: S1525-0016(17)30122-3. doi: 10.1016/j.ymthe.2017.03.023. [Epub ahead of print] Review.
http://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(17)30122-3
- Home
-
Products and Applications
-
Morpholino Antisense Oligos
- Why Morpholinos?
- Optimal Target Choice
- Methods/Protocols
- Morpholino Products and Properties
- End Modifications and Controls
- Blocking miRNAs
- Blocking Localization Elements of mRNA
- Modify poly-A Tailing
- Other targets: ncRNA, repeat elements, etc.
- External guides for use with RNase P
- Diagnostics
- Uses for Pretargeting & Crosslinking
- Therapeutics
- Bacteria Applications
- Protist Applications
- Insect Applications
-
Morpholino Antisense Oligos
- Ordering
- Customer Support
- Morpholino Publications Database
- FAQ
- About Us
- Contact Us
Add new comment